Comparison of four commercial methods for determining temocillin susceptibility of Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 832-834

  Rodriguez Villalobos, Hector ^a   Cardentey Reyes, Alina ^a   Thiroux, Christine ^a   Nonhoff, Claire ^a   Struelens, Marc J ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Disc diffusion; Etest; Vitek 2

Indexed keywords

BACTERIAL DNA; TEMOCILLIN;

ACCURACY; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISK DIFFUSION; DNA SEQUENCE; EPSILOMETER TEST; ESCHERICHIA COLI; GENOTYPE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; WILD TYPE;

ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLINS; SENSITIVITY AND SPECIFICITY;

EID: 62549085620     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp035     Document Type: Letter

References (6)

1. Rodriguez-Villalobos H, Malaviolle V, Frankard J et al. In vitro activity of temocillin against extended spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2006; 57: 771-4.
2. Livermore DM, Hope R, Fagan EJ et al. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006; 57: 1012-4.
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
4. Fuchs PC, Barry AL, Thomsberry C et al. Interpretative criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol 1985; 4: 30-3.
5. Andrews JM, Jevons G, Walker J et al. Temocillin susceptibility by BSAC methodology. J Antimicrob Chemother 2007; 60: 185-7.
6. De Jongh R, Hens R, Basma V et al. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: Stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008; 61: 382-8.